의약품 및 바이오테크놀러지의 유통 거래는 기업이 유통 거래를 하는 방법과 이유에 대한 자세한 이해와 분석을 제공합니다. 본 보고서는 2020년부터 2025년까지의 유통 거래에 대한 상세한 정보를 제공합니다.
이 보고서는 당사자 간에 발표된 유통 거래의 지불 조건에 대한 액세스를 제공합니다. 이 데이터는 지불 조건 및 기타 거래 조건에 대한 유용한 인사이트를 제공합니다.
파트너 후보자가 협상한 거래 조건의 유연성을 이해하면 협상 과정에서 협상 과정에서 무엇을 기대할 수 있는지에 대한 중요한 인사이트를 얻을 수 있습니다. 많은 중소기업들이 지불 조항에 대한 세부 사항을 요구할 것으로 예상되지만, 지불의 발동 및 권리 이전 방식에 대해서는 세부 사항에 악마가 숨어있습니다. 보도자료나 데이터베이스에는 없는 이 인사이트는 계약서에서 얻을 수 있습니다.
본 보고서는 Current Agreements의 거래 및 제휴 데이터베이스에 기록된 2020년 이후 발표된 유통 거래를 포괄적으로 나열하고, 가능한 경우 재무 조건을 포함하며, 기업과 파트너가 증권거래위원회에 제출한 실제 유통 거래 문서의 온라인 사본에 대한 링크도 제공합니다.
본 보고서의 첫 번째 장에서는 유통 거래와 비즈니스 활동에 대해 설명합니다.
1장에서는 본 보고서의 소개를, 2장에서는 유통 동향에 대한 개요와 분석, 그리고 거래 유형별 장점에 대해 설명합니다.
제 3장에서는 유통 안건의 구조에 대해 개괄적으로 살펴봅니다.
4장에서는 2020년 이후 주요 유통 딜을 검토합니다. 거래는 헤드라인 가치별로 나열되어 있으며, SEC에 공시된 계약서가 있는 거래에 대해서는 Current Agreements Deal and Alliances 데이터베이스를 통해 링크를 통해 온라인으로 계약서에 접근할 수 있습니다.
5장에서는 가장 활발한 유통 및 거래 업체 상위 25개사의 종합적인 목록이 수록되어 있습니다. 각 거래 제목은 Current Agreements의 Deal & Alliance 데이터베이스를 통해 전체 거래 기록의 온라인 버전에 링크되어 있으며, 가능한 경우 실제 계약 문서에도 링크되어 있어 각 거래 기록에 대한 온디맨드 접근이 용이합니다.
6장에서는 계약 문서가 입수 가능한 경우, 2020년 이후 체결 및 발표된 유통 거래를 기업 A-Z, 치료법, 기술, 업종별로 분류하여 포괄적이고 상세하게 검토하고 있습니다. 계약서를 통해 유통 거래와 관련하여 당사자 간에 합의된 실제 거래 조건에 대한 자세한 인사이트를 얻을 수 있습니다.
거래 디렉토리에는 2020년 이후 발표된 모든 유통 거래의 종합적인 목록이 포함되어 있습니다. 각 목록은 기업 A-Z, 치료 분야, 기술 유형별로 거래 디렉토리로 구성되어 있습니다. 각 거래 제목은 하이퍼링크를 통해 실제 계약 문서를 포함한 거래 기록의 온라인 버전으로 연결됩니다.
또한, 본 보고서에는 2020년 이후 거래 메이킹의 동향과 활동을 보여주는 다양한 도표가 포함되어 있습니다.
목차
주요 요약
제1장 소개
제2장 유통 거래 동향
- 소개
- 유통 거래의 정의
- 2020년 이후 유통 거래 동향
- 유통 거래 연도별 추이, 2020-2025년
- 개발 단계별 유통 거래, 2020-2025년
- 업계 부문별 유통 거래, 2020-2025년
- 치료 분야별 유통 거래, 2020-2025년,
- 기술 유형별 유통 거래, 2020-2025년
- 가장 활발한 기업별 유통 거래, 2020-2025년
- 순수 유통 거래의 속성
- 다중 구성요소 거래의 유통 속성
- 파트너를 조정하여 유통 거래가 작동하도록 한다.
제3장 유통 거래 구조 개요
- 소개
- 판매 계약 구조
- 광범위한 제휴 계약의 일부인 배포 권한
제4장 주요 유통 거래
제5장 가장 활발한 유통 거래업체 주요 25개사
- 소개
- 가장 활발한 유통 거래업체 주요 25개사
제6장 계약 디렉토리를 포함한 유통 거래
- 소개
- 계약별 유통 거래, 2020-2025년
- 거래 디렉토리
- 거래 디렉토리 기업별 유통 거래 리스트(AZ)
- 거래 디렉토리 치료 분야별 유통 거래
- 거래 디렉토리 기술 유형별 유통 거래
- 조사 회사에 대해
- 현재 제휴
- 현재 계약
- Current Partnering에서의 최근 보고서 제목
ksm
Distribution Deals in Pharmaceuticals and Biotechnology provides a detailed understanding and analysis of how and why companies enter distribution deals.
Fully revised and updated, the report provides details of distribution deals from 2020 to 2025.
The report provides access to distribution deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms.
Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred - contract documents provide this insight where press releases and databases do not.
This report contains a comprehensive listing of distribution deals announced since 2020 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual distribution contract documents as submitted to the Securities Exchange Commission by companies and their partners.
The initial chapters of this report provide an orientation of distribution dealmaking and business activities.
Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview and analysis of the trends in distribution as well as a discussion on the merits of the type of deal.
Chapter 3 provides an overview of the structure of distribution deals.
Chapter 4 provides a review of the leading distribution deals since 2020. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.
Chapter 5 provides a comprehensive listing of the top 25 most active distribution dealmaker companies. Each deal title links via Current Agreements deals and alliances database to an online version of the full deal record, and where available, the actual contract document, providing easy access to each deal record on demand.
Chapter 6 provides a comprehensive and detailed review of distribution deals organized by company A-Z, therapy, technology and industry type signed and announced since 2020 where a contract document is available. Contract documents provide an indepth insight into the actual deal terms agreed between the parties with respect to the distribution deal.
The deal directory includes a comprehensive listing of all distribution deals announced since 2020. Each listing is organized as a deal directory by company A-Z, therapeutic area and technology type. Each deal title links via hyperlink to an online version of the deal record including, where available, the actual contract document.
The report also includes numerous table and figures that illustrate the trends and activities in distribution dealmaking since 2020.
In conclusion, this report provides everything a prospective dealmaker needs to know about distribution alliances.
Key benefits
Distribution Deals in Pharmaceuticals and Biotechnology provides the reader with the following key benefits:
- Understand deal trends since 2020
- Browse distribution deals
- Benchmark analysis - identify market value of transactions
- Financials terms
- Directory of deals by company A-Z, therapy focus and technology type
- Leading deals by value
- Most active dealmakers
- Identify assets and deal terms for each transaction
- Access contract documents - insights into deal structures
- Due diligence - assess suitability of your proposed deal terms for partner companies
- Save hundreds of hours of research time
Report scope
- Distribution Deals in Pharmaceuticals and Biotechnology is intended to provide the reader with an in-depth understanding of the distribution trends and structure of deals entered into by leading biopharma companies worldwide.
Distribution Deals in Pharmaceuticals and Biotechnology includes:
- Trends in distribution dealmaking in the biopharma industry
- Overview of distribution deal structure
- Directory of distribution deal records covering pharmaceutical and biotechnology
- The leading distribution deals by value
- Most active distribution dealmakers
- The leading distribution partnering resources
In Distribution Deals in Pharmaceuticals and Biotechnology, the available deals are listed by:
- Company A-Z
- Headline value
- Therapeutic area
- Technology type
- Each deal title links via Weblink to an online version of the actual deal record, providing easy access to each contract document where available.
- Distribution Deals in Pharmaceuticals and Biotechnology provides comprehensive access to available records for distribution deals, including contract documents where available.
Analyzing contract agreements allows due diligence of:
- What are the rights granted or optioned?
- What rights are granted by the agreement?
- What exclusivity is granted?
- What is the payment structure for the deal?
- How are sales and payments audited?
- What is the deal term?
- How are the key terms of the agreement defined?
- How are intellectual property rights handled and owned?
- Who is responsible for commercialization?
- Who is responsible for development, supply, and manufacture?
- How is confidentiality and publication managed?
- How are disputes resolved?
- Under what conditions can the deal be terminated?
- What happens when there is a change of ownership?
- What sublicensing and subcontracting provisions have been agreed?
- Which boilerplate clauses does the company insist upon?
- Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
- Which jurisdiction does the company insist upon for agreement law?
Table of Contents
Executive Summary
Chapter 1 - Introduction
Chapter 2 - Trends in distribution dealmaking
- 2.1. Introduction
- 2.2. Definition of distribution deals
- 2.3. Trends in distribution deals since 2020
- 2.3.1. Distribution dealmaking by year, 2020-2025
- 2.3.2. Distribution dealmaking by phase of development, 2020-2025
- 2.3.3. Distribution dealmaking by industry sector, 2020-2025
- 2.3.4. Distribution dealmaking by therapy area, 2020-2025
- 2.3.5. Distribution dealmaking by technology type, 2020-2025
- 2.3.6. Distribution dealmaking by most active company, 2020-2025
- 2.3.7. Attributes of pure distribution deals
- 2.3.8. Attributes of distribution in multi-component deals
- 2.4. Aligning partners to make the distribution agreement work
Chapter 3 - Overview of distribution deal structure
- 3.1. Introduction
- 3.2. Distribution agreement structure
- 3.3. Distribution rights as part of a wider alliance agreement
Chapter 4 - Leading distribution deals
- 4.1. Introduction
- 4.2. Top distribution deals by value
Chapter 5 - Top 25 most active distribution dealmakers
- 5.1. Introduction
- 5.2. Top 25 most active distribution dealmakers
Chapter 6 - Distribution deals including contracts directory
- 6.1. Introduction
- 6.2. Distribution deals with contracts 2020-2025
- Deal directory
- Deal directory - distribution dealmaking by companies A-Z
- Deal directory - distribution dealmaking by therapy area
- Deal directory - distribution dealmaking by technology type
- About Biopharma Research
- Current Partnering
- Current Agreements
- Recent report titles from Current Partnering
TABLE OF FIGURES
- Figure 1: Definition of distribution
- Figure 2: Trends in distribution deal announcements, 2020-2025
- Figure 3: Distribution deals signed at each phase of development, 2020-2025
- Figure 4: Distribution deals by industry sector, 2020-2025
- Figure 5: Distribution deals by therapy area, 2020-2025
- Figure 6: Distribution deals by technology type, 2020-2025
- Figure 7: Top 25 most active distribution dealmakers, 2020-2025
- Figure 8: Issues in implementing distribution agreements
- Figure 9: Distribution agreements - what should a contract include?
- Figure 10: Components of the distribution deal structure
- Figure 11: Top distribution deals by value 2020-2025
- Figure 12: Most active distribution dealmakers 2020-2025
